NeuExcell Therapeutics

NeuExcell Therapeutics

  • Founded: 2016
  • Location: Philadelphia, PA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Ischemic cortical stroke
  • Drug types: CVV, NEU, GEN, OPH, ONC, X_X
  • Lead product: NXL-001
  • Product link:
  • Funding: 10-50M

job board

Short description:

Gene Therapy for Neural Regeneration & Repair

Drug notes:

NXL-002 RD/Clin0 Huntington's disease; NXL-003 RD/Clin0 ALS; 6 undisclosed programs RD retinal diseases, glioma, Alzheimer's, epilepsy, TBI, Parkinson's

Long description:

NeuExcell Therapeutics is developing gene therapies to treat neurodegenerative diseases. Loss of neuronal function is a common feature of neurodegenerative diseases causing millions of patients worldwide to suffer. NeuExcell is investigating the latest biotechnologies to find effective therapies to regenerate neural tissue in damaged areas. NeuExcell’s approach is supported by the discovery of in vivo astrocyte-to-neuron (AtN) conversion using gene therapy. Taking advantage of AtN, NeuExcell has shown in animal models of Huntington’s disease and stroke that the therapy repairs neural tissues, motor function and mitigates cognitive deficits. NeuExcells third leading candidate program is in Amyotrophic Lateral Sclerosis.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy